Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Cytokinetics Inc (CYTK) vs iShares Core S&P 500 ETF (IVV) Price & Performance

Cytokinetics IncTrade
iShares Core S&P 500 ETFTrade

Price performance (Past 24H)

Key statistics

Cytokinetics Inc vs iShares Core S&P 500 ETF — how do they compare? Cytokinetics Inc trades at $77.57 (market cap $10.63B), while iShares Core S&P 500 ETF trades at $776.06. The key difference: iShares Core S&P 500 ETF is trading nearer its 52-week high, Cytokinetics Inc nearer its low. Which is the better fit depends on your goals.

CYTKIVV
Market Cap
$10.63B
Sector
TechnologyBroad Market / Factor
52-Week High
$87.26$776.81
52-Week Low
$34.31$634.93
Enterprise Value
$10.74B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Cytokinetics Inc

CYTK trades at $77.07, down 0.54% on the day, with a bearish technical signal from moving averages. The company reported a Q2 2026 loss of $1.50 per share, beating estimates, but revenue of $68 million in 2026 reflects a net loss margin of -1,321.12%. Recent UK approval for MYQORZO and positive NICE guidance provide commercial momentum, yet high SG&A costs and negative cash flow from operations highlight ongoing financial strain.

The outlook hinges on MYQORZO's commercial execution and label expansion, with a consensus price target of $111.14 implying 44% upside. Risks include sustained cash burn, competitive pressure, and reliance on aficamten's clinical success. Analyst sentiment is overwhelmingly bullish, but profitability remains distant.

iShares Core S&P 500 ETF

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Cytokinetics Inc

Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.

Read more on CYTK

About iShares Core S&P 500 ETF

IVV tracks the performance of the S&P 500 Index, offering low-cost exposure to 500 of the largest US companies. It is a cornerstone for long-term investors seeking broad growth in the US stock market.

Read more on IVV